BNP GER Week ended 31 Jul 2026

Weekly Investor Report

BNP Paribas SA · Financial Services · Banks - Regional

Open interactive chart View report data
Latest close 109.7 EUR
3.7% latest week
Weekly setup

Constructive, but selective

The weekly trend is active. Price is 20.3% above the Trend Line and sits at 99.2% of its 52-week range. The latest completed week returned 3.7%, after a 6.9% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is inexpensive relative to peers. The latest news-sentiment score is 56/100. Near-term considerations: price is close to its 52-week high.

Setup score 84 out of 100
Latest Close 109.7 EUR 31 Jul 2026
1W Return 3.7% latest completed week
4W Return 6.9% short-term follow-through
12W Return 23.4% quarterly tape
Trend Breadth 82.7% 43 of 52 weeks active
Volume Ratio 2.7x vs 13-week average
What is working
  • The trend backdrop is active with a 31-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • 3 reversal markers appear in the recent smart-money tape.
What to watch next
  • Price is close to its 52-week high; watch for continuation or exhaustion.
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 3.7% Latest completed week; four-week move 6.9%. Indicator stack 90/72 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Positive 58.22% Historical one-week expectancy contributes to the evidence score when direction is confirmed. News sentiment 56/100 28 relevant articles in the latest sentiment read.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 20.3% above the Trend Line and sits at 99.2% of its 52-week range. The latest completed week returned 3.7%, after a 6.9% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 2.7x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.9812-week average 0.77

12-week confirmation

Trend active12/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure8/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership12/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.98Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers33 reversal markers

No recent accumulation markers. 3 reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 6.9% over four weeks, 23.4% over 12 weeks, and 52.6% over one year. The current trend has remained active for 31 consecutive weeks.

Performance by holding period

1W3.7%
4W6.9%
12W23.4%
26W23.9%
52W52.6%
Active trend streak31 weeks
Active weeks in one year43
Trend breadth82.7%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure1.18Latest activity-pressure read.
Pressure change12.2%Four-week change in activity pressure.
Leadership24.64Latest relative-leadership reading.
RS change30.2%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is inexpensive relative to peers.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 73% Model confidence 70%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength96/100Blend of value, momentum, and quality. Underlying universe rank 5; rank 1 is best.
Value85/100Relative valuation strength. Underlying universe rank 16; rank 1 is best.
Quality66/100Profitability and accounting quality. Underlying universe rank 35; rank 1 is best.
Momentum83/100Medium-term price momentum. Underlying universe rank 18; rank 1 is best.
Growth67/100Revenue and earnings growth. Underlying universe rank 34; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
9.4x
Price divided by trailing earnings.
Price / sales
1.5x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
15.6%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-
Gross profit retained from each unit of revenue.
Operating margin
-
Operating profit retained from revenue.
Free-cash-flow margin
55.2%
Free cash flow generated from revenue.
Return on invested capital
-
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
4.5%
Latest one-year revenue growth.
EPS growth
7.4%
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
6/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
4.9%
Cash dividends relative to market value.
Buyback yield
11.5%
Net share repurchases relative to market value.
Shareholder yield
16.4%
Dividend yield plus net buyback yield.
Net debt / EBITDA
-
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment56/100

Weighted news tone is neutral across 28 relevant articles.

9 positive · 17 neutral · 2 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-0.3%Distance below the 52-week high.
13-week volatility2.3%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher17 of 269 weeks finished lower.
Best week+8.5%Week of 10 Apr.
Worst week-9.5%Week of 6 Mar.
Latest week+3.7%Week of 31 Jul.

Shape of recent returns

Strong gains4
Modest gains13
Flat weeks0
Modest losses6
Sharp losses3
Recent vol2.3%13-week weekly-return volatility.
Base vol3.7%52-week weekly-return volatility.
Up/down split34/18Count of positive and negative weeks in the 52-week window.
Average skew3.0% / -3.1%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape83/100

Trend, activity pressure, participation, and risk combine to a 83/100 tape read.

 Indicator analysis78/100

Latest 12-week confirmation: trend 12/12, activity pressure 8/12, relative leadership 12/12.

Activity pressure 0.98; 3 reversal markers Next-Week ExpectancyPositive 58.22%

Next-week expectancy is positive with a 58.22% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors82/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 2 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment56/100

Weighted news tone is neutral across 28 relevant articles.

BNP Paribas Exane downgrades Rentokil stock rating on restructuring concerns Insiders50/100

No recent insider transaction evidence is stored.

 Earnings50/100

No stored earnings event is currently attached to this ticker.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 2026109.7 EUR3.7%91.21 EUR65.30 EUR1.1824.6470.1KOn
24 Jul 2026105.8 EUR3.8%90.21 EUR64.91 EUR1.0923.6126.4KOn
17 Jul 2026102.0 EUR1.4%89.29 EUR64.55 EUR1.0721.2121.2KOn
10 Jul 2026100.6 EUR-2.0%88.50 EUR64.20 EUR1.1119.1826.2KOn
3 Jul 2026102.6 EUR1.4%87.68 EUR63.86 EUR1.0518.9321.6KOn
26 Jun 2026101.2 EUR-0.3%86.70 EUR63.49 EUR0.7723.284.6KOn
19 Jun 2026101.5 EUR5.0%85.71 EUR63.15 EUR0.5022.871.7KOn
12 Jun 202696.72 EUR3.4%84.60 EUR62.79 EUR0.1919.4711.4KOn
5 Jun 202693.56 EUR0.5%83.61 EUR62.47 EUR-0.1715.614.0KOn
29 May 202693.10 EUR3.6%82.61 EUR62.17 EUR-0.2413.9729.9KOn
22 May 202689.88 EUR3.7%81.68 EUR61.87 EUR-0.3311.4437.9KOn
15 May 202686.71 EUR-2.5%80.90 EUR61.60 EUR-0.4212.1130.9KOn
8 May 202688.92 EUR2.6%80.43 EUR61.34 EUR-0.3513.6046.9KOn
1 May 202686.69 EUR0.2%79.91 EUR61.06 EUR-0.3611.4544.9KOn
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.